Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We have two areas of focus: 1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, acute radiation syndrome, and emerging and antibiotic resistant infectious disease.
Soligenix cares deeply and works tirelessly to improve the lives of patients worldwide. Our leadership and our Board of Directors have decades of experience in the biopharmaceutical industry, which includes unique expertise in developing orphan/rare disease therapies.
We are committed to transforming research into reality.